Non-radiographic axial spondyloarthritis (AXSPA) Program in Pharmaceutical Benefits Scheme (PBS) 012-18112216

This document outlines details of PBS-subsidised biological medicines for patients with non-radiographic axial spondyloarthritis (AXSPA).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB255 form	Written S85: bimekizumab certolizumab pegol golimumab secukinumab upadacitinib	Yes	OPA	Must be treated by a: rheumatologist clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis	No
Grandfather PB353 form	Written S85: bimekizumab	Yes	OPA	Must be treated by a: rheumatologist clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis	No
Continuing	Telephone Electronic S85: bimekizumab certolizumab pegol golimumab secukinumab upadacitinib	No	OPA	Must be treated by a: rheumatologist clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis	Yes
Change or: Recommencement after a break (< 5 years), or Recommencement - after a break (> 5 years)	Telephone Electronic S85: bimekizumab certolizumab pegol golimumab secukinumab upadacitinib	No	OPA	Must be treated by a: rheumatologist clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis	Yes
Balance of supply	Telephone Electronic S85: bimekizumab certolizumab pegol golimumab secukinumab upadacitinib	No	OPA	Must be treated by a: rheumatologist clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis	Yes

Operational Information